Bartalena L, Baldeschi L, Dickinson J, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curr N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marin M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European Group on Graves Orbitopathy (EUGOGO) on management of Graves Orbitopathy
[Abstract]2020 Feb 19;522(4):862-868
Weight loss drugs became prevalent around 2016-2017, when Semaglutide was first introduced to the market as a treatment for type 2 diabetes
In addition to removing mycotoxins with binders and through detoxification, the other critical steps are repairing the inflammatory response and oxidative damage
40,